Metacrine, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2015-01-01
- Employees
- 32
- Market Cap
- -
- Website
- http://www.metacrine.com
Study to Evaluate MET642 in Patients With NASH
- First Posted Date
- 2021-02-26
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- Metacrine, Inc.
- Target Recruit Count
- 215
- Registration Number
- NCT04773964
- Locations
- 🇺🇸
Pinnacle Research, San Antonio, Texas, United States
Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes and NASH
Phase 2
- Conditions
- Fatty LiverType 2 DiabetesDiabetes Type 2DiabetesNAFLDNASHNASH - Nonalcoholic SteatohepatitisFatty Liver, Nonalcoholic
- Interventions
- First Posted Date
- 2021-01-11
- Last Posted Date
- 2021-06-01
- Lead Sponsor
- Metacrine, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT04702490
- Locations
- 🇺🇸
Metacrine Investigative Site, San Antonio, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath